Medpace (MEDP) Stock Rating Reaffirmed by Mitsubishi UFJ Financial Group

Medpace (NASDAQ:MEDP)‘s stock had its “neutral” rating reissued by equities research analysts at Mitsubishi UFJ Financial Group in a research note issued to investors on Friday. They currently have a $40.00 price objective on the stock. Mitsubishi UFJ Financial Group’s price objective suggests a potential upside of 6.87% from the stock’s current price.

A number of other brokerages have also weighed in on MEDP. Credit Suisse Group reissued an “outperform” rating and issued a $42.00 price target (up previously from $41.00) on shares of Medpace in a report on Tuesday, February 27th. Jefferies Group reissued a “hold” rating and issued a $35.00 price target on shares of Medpace in a report on Thursday, March 1st. Robert W. Baird set a $35.00 price target on shares of Medpace and gave the company a “hold” rating in a report on Tuesday, April 10th. Wells Fargo lowered their price target on shares of Medpace from $38.00 to $35.00 and set a “market perform” rating for the company in a report on Wednesday, February 28th. Finally, BidaskClub raised shares of Medpace from a “buy” rating to a “strong-buy” rating in a report on Friday, February 16th. Nine equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $37.83.

Shares of Medpace stock opened at $37.43 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 0.67 and a quick ratio of 0.67. The company has a market capitalization of $1,306.12, a P/E ratio of 24.41, a P/E/G ratio of 1.39 and a beta of 0.09. Medpace has a fifty-two week low of $21.76 and a fifty-two week high of $39.64.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 26th. The company reported $0.39 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.01. The business had revenue of $99.45 million during the quarter, compared to analyst estimates of $97.25 million. Medpace had a net margin of 8.97% and a return on equity of 10.55%. Medpace’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.35 earnings per share. equities analysts predict that Medpace will post 1.88 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MEDP. MetLife Investment Advisors LLC acquired a new stake in Medpace during the 4th quarter worth $137,000. SG Americas Securities LLC acquired a new stake in Medpace during the 4th quarter worth $151,000. Atria Investments LLC acquired a new stake in Medpace during the 4th quarter worth $211,000. We Are One Seven LLC acquired a new stake in Medpace during the 4th quarter worth $211,000. Finally, Koch Industries Inc. acquired a new stake in Medpace during the 4th quarter worth $279,000. 24.63% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This story was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3373495/medpace-medp-earns-neutral-rating-from-analysts-at-mitsubishi-ufj-financial-group.html.

About Medpace

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Analyst Recommendations for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Financial Contrast: COCA-COLA HBC A/ADR  versus Coca-Cola European Partners
Financial Contrast: COCA-COLA HBC A/ADR versus Coca-Cola European Partners
Financial Comparison: Sunoco  & Macquarie Infrastructure
Financial Comparison: Sunoco & Macquarie Infrastructure
Schroders  Stock Rating Upgraded by Zacks Investment Research
Schroders Stock Rating Upgraded by Zacks Investment Research
Zacks Investment Research Downgrades American Eagle Outfitters  to Sell
Zacks Investment Research Downgrades American Eagle Outfitters to Sell
Zacks: Analysts Anticipate American Equity Investment Life Holding  Will Post Earnings of $0.85 Per Share
Zacks: Analysts Anticipate American Equity Investment Life Holding Will Post Earnings of $0.85 Per Share
Daily Journal Co.  Director John Patrick Et Al Guerin Sells 79 Shares of Stock
Daily Journal Co. Director John Patrick Et Al Guerin Sells 79 Shares of Stock


© 2006-2018 Ticker Report. Google+.